{"schema_version":"secwatch.filing_event.v1","accession":"0001730463-24-000076","form_type":"8-K","ticker":"AUTL","cik":"0001730463","company_name":"Autolus Therapeutics plc","filed_at":"2024-06-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.784423+00:00","generated_at":"2026-06-01T00:42:57.795201+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Autolus Therapeutics shareholders approve all nine resolutions at 2024 AGM","bullets":["Adoption of 2023 annual accounts passed with 190.78M votes for, 35.8K against.","Directors' remuneration report approved: 167.10M for, 23.69M against.","Ernst & Young LLP reappointed as auditors for the coming year.","All four director re-elections passed: Bain (99.52%), Butitta (98.36%), Itin (99.83%), Young (99.12%).","Board authorized to allot shares up to $8,400 nominal value (Resolution 8) and disapply pre-emption rights (Resolution 9)."],"urls":{"canonical":"https://secwatch.observer/filing/0001730463-24-000076","json":"https://secwatch.observer/filing/0001730463-24-000076.json","markdown":"https://secwatch.observer/filing/0001730463-24-000076.md","text":"https://secwatch.observer/filing/0001730463-24-000076.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730463/000173046324000076/0001730463-24-000076-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730463/000173046324000076/autl-20240628.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T00:42:57.795201+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}